Strand Therapeutics has raised seed funding to develop an mRNA engineering platform based on MIT research as it looks to assemble a pipeline of oncological drug candidates.
Strand Therapeutics, a US-based RNA gene therapy developer spun out from Massachusetts Institute of Technology (MIT), closed a $6m seed round on Tuesday involving Alexandria Venture Investments, the investment arm of life science real estate trust Alexandria Real Estate Equities.
The round was led by venture capital fund and incubator Playground Global with participation from VC firm Anri and a group of private investors.
Founded in 2017, Strand Therapeutics is working on a synthetic biology platform through which…
